Abstract:Abstract The RAS-RAF pathway is one of the most commonly dysregulated in human cancers. The activation of this pathway is tightly regulated with appropriate spatial and temporal signaling cues. The central step in activation of this pathway is the dimerization of RAF kinases. Recent advances in biochemical, enzymatic and structural characterization of various multiprotein complexes in this pathway provide insight into various modes of RAF activity modulation. Kinase RAF and its substrate MEK exist as a pre-formed complex prior to pathway activation. Multiple factors prevent MEK phosphorylation by RAF in this pre-formed complex, including phosphorylation of a Serine residue N-terminal to the kinase domain, which enables 14-3-3 to trap RAF as a monomer. One of our intriguing findings is that cellular ATP exerts a negative regulatory effect on RAF kinase and stabilizes the inactive conformation of RAF monomer. We characterize this negative regulatory effect of ATP of RAF kinase structurally by solving a RAF-ATP complex and enzymology. Upon membrane recruitment of RAF by RAS-GTP, dephosphorylation of the above-mentioned serine residue in RAF occurs by a multiprotein complex composed of phosphatase PP1C, a scaffolding protein SHOC2 and RAS-GTP. We solved the structure of this RAS-SHOC2-PP1C complex and performed a thorough enzymatic analysis of this complex for RAF dephosphorylation. Our results show that RAF specificity is determined by SHOC2 and RAS GTP is responsible for spatial localization both inactive RAF and SHOC2/PP1C to the membrane. This dephosphorylation results in RAF being stabilized as a dimer by 14-3-3, which now binds to phospho-serine residues C-terminal to the kinase domain (S729 in BRAF) in 2 RAF molecules. We solve a structure of the RAF-14-3-3 complex. 14-3-3 induced RAF dimerization increases activity of RAF ~500 fold. Further, oncogenic mutations in RAF and MEK occur basally in tumors, and additional mutations are induced upon pathway inhibitor treatment in the clinic, especially for recent KRAS-G12C treatments. These mutations include RAF mutations that either activate or inactivate the kinase activity of the mutated RAF, but nevertheless result in pathway activation. Our data suggests that these mutations appear to tilt the RAF monomer-dimer equilibrium towards RAF dimer. The molecular mechanism of how the MEK mutations active the pathway in poorly understood. Biochemical and structural characterization of these mutations occurring in MEK kinases suggests that the mechanism of activation is also likely functioning via promoting RAF dimerization. This RAF dimer promotion appears to mechanistically work by relieving the negative regulatory effect of RAF by ATP to result in the “just-right” amount of pathway activation to sustain tumor growth. A comprehensive understanding of the various factors modulating RAF dimerization in the context of normal cell and cancer cells that depend on this pathway can pave the way for more precise interventions for treatment of cancers that depend on the RAS pathway. Citation Format: Jawahar Sudhamsu, Nicholas Liau, Timothy Wendorff, Saeed Izadi, Luca Gerosa. Factors modulating RAF dimerization downstream of RAS – A mechanistic overview [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr PR02.

Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

Novel insights into the pathogenesis and treatment of NRAS mutant melanoma

Targeting RAS–ERK signalling in cancer: promises and challenges

Targeting the RAS upstream and downstream signaling pathway for cancer treatment

RAF inhibitors that evade paradoxical MAPK pathway activation

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

RAF and MEK Inhibitors in Non-Small Cell Lung Cancer

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

A patent review of RAF kinase inhibitors (2010-2018).

RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations

A Patent Review of RAF Kinase Inhibitors (2010–2018)

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Abstract PR02: Factors modulating RAF dimerization downstream of RAS – A mechanistic overview